Fig. 10: Apoptosis and improved tumor immune microenvironment induced by combination of anti-PD-1 antibody and Met@Man-MPs in organotypic slices from one liver cancer patient-derived tumor.
From: Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles
a The ratio of apoptotic tumor cells (CD45− cells) after the tumor slices from patient-derived tumor were treated with anti-human PD-1 antibody, Met@Man-MPs derived from THP-1-origniated macrophages or Met@Man-MPs plus anti-human PD-1 antibody at the concentration of anti-PD-1 antibody and Met of 20 and 40 μg mL−1 in the presence of PBMCs for 36 h, respectively. Data are presented as mean ± s.d. (n = 3 biologically independent samples; one-way ANOVA followed by Tukey’s HSD post-hoc test). (b–g) Percentages of M1-like TAMs (b), M2-like TAMs (c), CD8+ T (d), CD8+CD69+ T (e), CD8+IFN-γ+ T (f), and CD8+GzmB+ T cells (g) in the tumor slices from patient-derived tumor after treatment with anti-human PD-1 antibody, Met@Man-MPs derived from THP-1-origniated macrophages or Met@Man-MPs plus anti-human PD-1 antibody at the concentration of anti-PD-1 antibody and Met of 20 and 40 μg mL−1 in the presence of PBMCs for 36 h, respectively. Data are presented as mean ± s.d. (n = 3 biologically independent samples; one-way ANOVA followed by Tukey’s HSD post-hoc test). Source data are provided as a Source Data file.
